Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 6/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SDCBP | O00560 | 1/20 | 0.39 |
| ▸ | SDC2 | P34741 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2573117 | 0.87 | CTSK (0.45) | TRPA1PPARGPPARACTSSCTSK | |
| SCHEMBL3414715 | 0.87 | CTSK (0.51) | PPARGPPARAMAPTCTSSCTSK | |
| SCHEMBL3379781 | 0.87 | CTSK (0.51) | PPARGPPARAMAPTCTSSCTSK | |
| SCHEMBL4116995 | 0.87 | CTSK (0.51) | PPARGPPARAMAPTCTSSCTSK | |
| SCHEMBL14250689 | 0.87 | CTSK (0.51) | PPARGPPARAMAPTCTSSCTSK | |
| SCHEMBL844407 | 0.87 | CTSK (0.51) | PPARGPPARAMAPTCTSSCTSK | |
| SCHEMBL3824377 | 0.86 | TRPA1 (0.49) | TRPA1PPARGPPARAPRCPS1PR3 | |
| SCHEMBL22303774 | 0.86 | CTSK (0.41) | TRPA1PPARGPPARACTSSCTSK | |
| SCHEMBL2436816 | 0.86 | CTSS (0.46) | TRPA1ALDH1A1MAPTCTSSCTSK | |
| SCHEMBL4683822 | 0.86 | CTSK (0.46) | TRPA1ALDH1A1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436028-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARP & DOHME CORP (US) | 2013-05-07 | — | — | US | disclosed |
| US-20100197630-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197630-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | CETP, APOB, MTTP | TRPA1 2840/4885PPARG 181/4885PPARA 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.